News

Cynbiose receives €1.9 million ($2.1M) to launch CYNBIOME, preclinical excellence network on microbiome and infectious diseases

Cynbiose announces that it has procured financing of €1.9 million ($2.1M) under the third phase of the French Program ‘Investment for the Future’ (PiA3).

These funds will make it possible to launch CYNBIOME, the 1st excellence network on microbiome and infectious diseases based on the Non-Human Primate (NHP) model.

CYNBIOME is financed by the French government and the Auvergne-Rhône-Alpes region and is supported by Bpifrance (The French Public Bank of Investment).

Read the press release January 28, 2020

Cynbiose will attend the IABS scientific conference “New paths for sustainable solutions to tackle global and emerging infectious threats” – Lyon, February 27-28, 2020

On the occasion of its 65th anniversary, the IABS (International Alliance for Biological Standardization) and Lyonbiopole organize a scientific conference on February 27th and 28th, 2020 at the ENS on the theme of  “New paths for sustainable solutions to tackle global and emerging infectious threats”.

https://65.iabs.org

Cynbiose will attend BIO Europe Spring – Paris, March 23-25th, 2020

Contact us to arrange a meeting and discuss about your preclinical projects.

 

Cynbiose will attend the 3rd workshop on Probiotics and Gut Microbiotia – Lyon, February 4th 2020

Key event organized by Lyonbiopole, the “Probiotics and Intestinal Microbiota Day” brings together academic, clinical and industrial players (SMEs and large groups), around a thematic lecture on the modulation of the intestinal microbiota.

For this 3rd edition, the central theme “Yesterday’s antibiotics, next-generation probiotics and other new strategies for modulating the intestinal microbiota” will provide an opportunity to highlight product developments and their future challenges.

Contact us to meet our team during this day.

 

Cynbiose, Signia Therapeutics and the VirPath academic laboratory are partnering on an ambitious collaborative R&D project to advance the development of innovative therapeutic treatments in the field of respiratory infections.

The METABIOSE project aims to develop and characterize a translational model of metapneumovirus
infection (hMPV), then to validate in preclinical studies a drug repositioned as a pneumovirus inhibitor
from Signia Therapeutics’s portfolio, as well as a new nebulization delivery thanks to an approved
medical device.

Read the press release.

 

Cynbiose attends BioFIT – Marseille, December 10 & 11th, 2019

We are attending BioFIT in Marseille, a unique European event gathering academics, TTOs and research institutions.

We will be pleased to meet you there, contact us to arrange a meeting.

BioFIT website: https://www.biofit-event.com/

Cynbiose will attend I4ID congress – Lyon, December 4-5th 2019

Meet our scientific team at the third edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2019) taking place at the ENS in Lyon, France.

Contact us to arrange a meeting.

More information on http://www.i4id.org

Cynbiose will attend BIO Europe – Hamburg, November 11-13th 2019

We are attending BIO Fall in Germany. We will be pleased to meet you there, contact us to arrange a meeting.

Cynbiose attends the 3rd scientific workshop of the MARVELOUS project in the field of stroke – Lyon, October 4 2019

Cynbiose will present a new model and non invasive imaging results during the scientific communication on  “PET/MRI measurements of perfusion and blood brain barrier permeability in a stroke model”.

Cynbiose is part of the MARVELOUS project dedicated to « New MR imAging to pReVent cErebraL and myocardial reperfUSion injury »,

More information : http://www.rhu-marvelous.fr/main/en_GB/

Symposium “Innovative & integrated solution providers in translational research to develop immunotherapies” – Paris, September 30th 2019

Register for this one-day workshop co-organized by Cynbiose, Oncodesign, Aepodia, CERB and PharmaLex : an unparalleled network of key partners.

Don’t miss this unique event with keynote lectures and roundtables discussions to support your drug development projects. Cynbiose will lead the roundtable discussion  ” Unlocking the potential of immunotherapies and vaccines : relevance of non-human primates models”.

More information and registration on this event that will take place on Monday September 30th, 2019 (Maison de la Chimie, Paris (France): https://www.solution-providers-immunotherapies.com/